From Tuesday, October 19, 2021 12:00 AM
to Sunday, October 31, 2021 12:00 AM
to Sunday, October 31, 2021 12:00 AM
Ic Scriattoli Vetralla
Open in-person activity
Italian
Via Umberto I, 01010, Blera, Viterbo, ITA
Esplorare la griglia attraverso molteplici attività creative e stimolanti
-
Secondary school
-
Unplugged activities
Longitude: 12.02593
Latitude: 42.273835
Geoposition: 42.273835026320924,12.025930090819458
Nearby upcoming activities:
.png)
Neuro Biomarkers and Biosignatures Conference
Mon, Jun 9, 2025 9:00 AM
We are excited to invite you to the Neuro Biomarkers and Biosignatures (NBB) Conference 2025, taking place from June 9-10, 2025, in the historic city of Rome, Italy. This hybrid event will offer both in-person and virtual participation options, making it accessible to a global audience.
Join leading researchers, clinicians, and industry experts as we explore the latest advancements in neuro biomarkers and biosignatures. This conference promises to be a pivotal platform for discussing cutting-edge research, innovative technologies, and emerging trends in the field.
Event Highlights:
Dates: June 9-10, 2025
Location: Rome, Italy (Hybrid Event)
Format: In-person and Virtual Sessions
Topics: Neuro biomarkers, biosignatures, neurotechnology, clinical applications, and more.
Oligonucleotide Therapeutics and Delivery Conference
Mon, Jun 9, 2025 9:00 AM
Sciinov Group is proud to announce the Oligonucleotide Therapeutics and Delivery Conference, 09-10 June, 2025 in Rome, Italy. This year OTDC 2025 annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 09-10 June, 2025 at Rome, Italy.
Industry and academic experts deliver detailed case studies on antisense, RNA, GalNAc, aptamers, conjugates and other new modalities, paving the way for the next generation of targeted oligonucleotide therapeutics.